Objectives: For patients with unresectable or metastatic thymic epithelial neoplasms, few therapy options are available and outcomes are poor. This case series demonstrates that the combination of capecitabine and celecoxib may be a promising therapeutic option for these patients.
T hymic neoplasms, including thymic carcinomas and thymomas, are a heterogeneous group of cancers with a broad spectrum of clinical presentation and behavior. Thymomas are rare, with an annual incidence of 1.5 cases per million. 1 Despite this, they remain the most common primary anterior mediastinal mass. Thymic carcinomas are even more rare, with an annual incidence of 1.3 cases per million. Thymic carcinomas tend to have a more aggressive course and are more likely to be invasive. The 5-year survival rate for all stage thymomas is 79%, compared with only 40% for thymic carcinomas. [2] [3] [4] In the unresectable and metastatic settings, chemotherapy with or without radiation therapy is the standard of care, but patients characteristically respond poorly and outcomes are poor. 5 Five-year survival rates decrease from 100% and 81%, for stages I and II disease, respectively, to 17% with stage IVb disease. 6 Patients with thymic neoplasms are in need of more effective treatment options.
5-Fluorouracil, and its oral equivalent capecitabine, are second-line therapies for thymic epithelial neoplasms. Celecoxib, an oral selective inhibitor of the cyclooxygenase-2 (COX-2) enzyme that catalyzes the conversion of arachidonate to prostaglandin H2, plays a critical role in carcinogenesis, angiogenesis, and chemoresistance. [7] [8] [9] While limited data exist regarding the combination of these 2 agents in treating thymic epithelial neoplasms, there are data in animal models of pancreatic tissue that capecitabine and celecoxib have synergistic effects. 10 Modest clinic benefit has also been noted with the combination in advanced pancreaticobiliary cancers. 11 The current report describes the outcomes of 6 patients with recurrent thymic neoplasms treated with the combination of capecitabine plus celecoxib.
MATERIALS AND METHODS
In this study, 5 of the 6 patients were treated on a drugdrug interaction study of capecitabine and celecoxib in patients with advanced solid tumors (NCT01705106) conducted at the University of Chicago Comprehensive Cancer Center (1 patient was treated off protocol because of patient convenience). Patients were treated with celecoxib 200 mg by mouth twice daily. After 1 week, capecitabine was added at a dose of 1000 mg/m 2 (rounded to the nearest 500 mg) by mouth twice daily on days 1 to 14 every 21 days. If a dose reduction was required because of toxicity, therapy was held for 1 week and then the capecitabine dose was reduced to 750 mg/m 2 by mouth twice daily (rounded to the nearest 500 mg). Patients began enrolling on study in December 2012, with last therapy administered in April 2016.
RESULTS
The baseline characteristics, response to therapy, and reason for discontinuation for the thymic neoplasm patients are shown in Table 1 . Median progression-free survival for the entire cohort was 14.6 months. Five of the 6 patients remain alive at a median follow-up of 33.5 months. The most significant responses were seen in the thymic carcinoma patients, with 2 patients achieving a complete response and the third achieving a partial response. The clinical course of these 3 thymic carcinoma patients is depicted in Figure 1 . The radiographic response of patient #1 is shown in Figure 2 .
The most common adverse event noted was palmarplantar erthryodysethesia (PPE). Four of 6 patients developed grade 3 PPE that required dose reduction of capecitabine therapy. Otherwise, no Grade 3 or 4 adverse events were reported among these patients.
Molecular analysis was performed on tumor tissue from patients 1, 3, and 4 by gene sequencing with the Foundation One assay (Foundation Medicine; Cambridge, MA). The genomic alterations identified are documented in Table 2 . Patient 4 did have an MEN1 mutation identified. He had no personal or family history of pancreatic endocrine tumors, pituitary adenomas, or parathyroid adenomas. Germline testing for MEN1 mutations was not performed on this patient. All 3 patients had loss or inactivating mutations of cyclin-dependent Kinase inhibitor 2A (CDKN2A).
DISCUSSION
Of the 6 patients described, an objective response was noted in 3 of 6 patients. The responses were most notable in the thymic carcinoma patients. Two of the thymic carcinoma patients had complete responses. The third had a partial response with an 80% reduction in target lesions by RECIST version 1.1. Best response for the other patients included stable disease for both thymoma patients and progressive disease for the thymic neuroendocrine patient. Other than grade 3 PPE, which developed in 4 of 6 patients and required a dose reduction, the regimen was well tolerated.
Of the 3 patients with genomic profiling, loss or inactivating mutations in CDKN2A were noted in all of them. To our knowledge, there is no available data suggesting CDKNAmutated tumors may be more prone to respond to either capecitabine or celecoxib therapy. This seems to be a common mutation in thymic neoplasms, with studies demonstrating loss of expression in 18.2% to 38% of the cases and correlating with higher recurrence rates and shorter overall survival. 12, 13 Currently no targeted agents exist for these mutations, though a phase I clinical trial is currently evaluating a pan-Aurora kinase inhibitor in patients with CDKN2A-deficient tumors (NCT02540876), with accrual still ongoing. 14 Limitations of this study include the small sample size and also the lack of comparison with capecitabine monotherapy. Without this comparison, the exact impact of celecoxib cannot be confirmed, as limited data already exist suggesting that capecitabine and 5-Fluoruracil can be effective in the treatment of thymic neoplasms. These data include a phase II study of 30 patients treated with capecitabine in combination with gemcitabine that demonstrated responses in 12 patients. 15 Case reports have also demonstrated efficacy of 5-fluorouracil, 16, 17 and a small case series demonstrated efficacy of Six patients and their responses to capecitabine/celecoxib. *Concern for vascular invasion of tumor led to cessation of therapy despite only 1.1% increase in tumor size. CR indicates complete response, PD, progressive disease, PR, partial response, SD, stable disease. second-line S1, an oral fluoropyrimidine agent, in thymic carcinoma. 18 Despite this, the durable responses and number of complete responses in the thymic carcinoma patients in this case series is notable and seems to improve on existing data. For instance, none of the thymic carcinoma patients in the capecitabine + gemcitabine phase II trial had a complete response and 63% of patients had disease progression within 2 months of the last dose of systemic therapy. And while clinical data are lacking, preclinical data demonstrating the antiapoptotic effect of celecoxib 19 and the previously mentioned synergistic effect of celecoxib with capecitabine 17 support the possibility of this combination improving outcomes compared with capecitabine monotherapy.
This case series reinforces the role of capecitabine in management of thymic epithelial neoplasms and suggests that capecitabine plus celecoxib may be an effective and welltolerated treatment option for patients with advanced thymic malignancies, especially thymic carcinoma. Larger studies should be carried out to establish the efficacy of capecitabine plus celecoxib in thymic carcinoma, and to clarify whether monotherapy with capecitabine would be similarly effective. 
